Cell & Gene Therapy Glossary
A comprehensive reference of terms used in cell therapy, gene therapy, and starting material procurement. This glossary covers key concepts relevant to researchers, clinical teams, and procurement professionals working with cell-based therapeutics.
A
Allogeneic
Derived from a donor who is genetically different from the recipient. Allogeneic cell therapies use cells from healthy donors rather than the patient, enabling off-the-shelf manufacturing. OrganaBio provides allogeneic starting materials including cord blood-derived NK cells and T cells.
Apheresis
A procedure that separates specific blood components (such as white blood cells) from a donor’s blood, returning the remaining components to the donor. Leukapheresis specifically collects leukocytes. OrganaBio’s subsidiary HemaCenter operates FDA-registered apheresis collection centers.
Autologous
Derived from the patient’s own cells. Autologous cell therapies require collecting cells from each individual patient, processing them, and returning them to the same patient. Fresh leukopaks are commonly used as starting material for autologous CAR-T manufacturing.
B
Biopreservation
The process of preserving biological materials for future use while maintaining cell viability and function. Includes cryopreservation (freezing) and hypothermic storage (cold but not frozen).
B Cells
A class of lymphocytes identified by expression of CD19 and CD20, responsible for humoral immunity through antibody production. Subsets include naïve, memory, plasmablast, and plasma cells. OrganaBio offers primary human B cells isolated from peripheral blood leukopaks.
Buffy Coat
The fraction of a centrifuged blood sample containing white blood cells and platelets, located between the plasma and red blood cell layers. A less concentrated alternative to a leukopak for PBMC isolation.
C
CAR-T (Chimeric Antigen Receptor T Cell)
A type of immunotherapy where a patient’s or donor’s T cells are genetically modified to express a chimeric antigen receptor that targets specific cancer cells. CAR-T manufacturing requires high-quality T cell starting materials, typically from leukopaks.
CAR-NK (Chimeric Antigen Receptor Natural Killer Cell)
Similar to CAR-T but using NK cells as the effector cell. Cord blood-derived NK cells are increasingly used for CAR-NK development because of their naive phenotype and amenability to genetic modification.
CD3+
A cell surface marker present on all T lymphocytes. CD3+ selection is used to isolate pan T cells from blood products. OrganaBio’s LeukoPAC-T and ImmunoPAC-T products provide CD3+ T cells.
CD34+
A cell surface marker for hematopoietic stem and progenitor cells. CD34+ cells are used in transplantation, gene therapy, and regenerative medicine research. OrganaBio’s HematoPAC-HSC provides CD34+ cells from cord blood.
CD56+
A cell surface marker for natural killer (NK) cells. CD56+ selection is used to isolate NK cell populations for immunotherapy research and CAR-NK development.
Cell Viability
The percentage of living cells in a sample. Higher viability indicates better quality starting material and improved downstream results. OrganaBio achieves 99.1% average cell viability through co-located collection and processing (under 30 minutes from draw to processing).
cGMP (Current Good Manufacturing Practice)
FDA-enforced regulations ensuring pharmaceutical and biologic products are consistently produced and controlled according to quality standards. OrganaBio operates cGMP manufacturing facilities with ISO 7 cleanrooms.
Chain of Custody
The documented, unbroken tracking of biological materials from collection through processing, storage, and delivery. Vertical integration allows OrganaBio to maintain chain of custody from donor consent through final product delivery.
Co-location
The practice of placing collection and processing facilities in close physical proximity to minimize transit time. OrganaBio’s collection centers and processing labs share a parking lot, enabling processing within 30 minutes of collection rather than the 18-36 hours typical of overnight shipping.
Cord Blood
Blood collected from the umbilical cord and placenta after birth. Cord blood contains hematopoietic stem cells, naive T cells, and NK cells with unique properties valuable for cell therapy. OrganaBio collects cord blood through its subsidiary GaiaGift.
Cryopreservation
The process of preserving cells by cooling them to very low temperatures (typically in liquid nitrogen at -196C). Validated cryopreservation protocols maintain cell viability and function for long-term storage.
CTDMO (Contract Technology Development and Manufacturing Organization)
An organization that provides both process development and manufacturing services for cell and gene therapy products. OrganaBio operates as a purpose-built CTDMO, distinguishing itself from general contract labs.
CAR-M
Chimeric antigen receptor macrophage therapy, an emerging modality in which macrophages are engineered to target solid tumors through phagocytosis and antigen presentation. OrganaBio supplies primary human macrophages used as starting material in CAR-M development.
Certificate of Analysis (CoA)
A quality document issued by a manufacturer that lists the test results for a specific lot of product against predefined acceptance criteria. Required for GMP starting materials and standard for OrganaBio products. OrganaBio CoAs include 8-color immunophenotyping, high-resolution HLA typing across six genes, and CBC data on the donor and final product.
Chain of Identity (CoI)
Documentation that links the identity of the donor, the starting material, and the final product across the entire manufacturing lifecycle. Required for autologous therapies and recommended for allogeneic products. Distinct from Chain of Custody, which tracks physical handling.
Cold Chain
The logistics system that maintains cells or biological products within a specified temperature range from collection through delivery. For fresh leukopaks, typically 2-8°C ambient-controlled shipping; for frozen products, vapor-phase liquid nitrogen dry shippers with continuous temperature monitoring.
Comparability Study
A formal study demonstrating that a change in manufacturing process, facility, or starting material does not adversely affect the quality, safety, or efficacy of a biological product. ICH Q5E provides the regulatory framework. OrganaBio supports comparability studies through donor-matched RUO and GMP material from the same recallable donor pool.
Controlled-Rate Freezing
A cryopreservation method in which the cooling rate is controlled to a defined profile, typically around 1°C per minute through the phase transition, to minimize ice-crystal damage and maximize post-thaw viability. Standard for GMP-grade cryopreserved cell products.
Critical Quality Attribute (CQA)
A physical, chemical, biological, or microbiological property that must be within an appropriate range to ensure product quality. Identified through quality by design (QbD) methodology and codified in ICH Q8.
Cross-Reactive Idiotype (CRM)
Context-dependent term in immunology referring to reactivity patterns that may confound donor matching in T cell therapy programs. Relevant where high-resolution HLA typing and TCR characterization are required.
D
Donor Recallability
The ability to recall the same qualified donor for repeat collections over time. Recallable donors ensure batch-to-batch consistency by providing the same biological starting material across R&D and clinical manufacturing. OrganaBio maintains 1,000+ recallable donors.
Dendritic Cells
Antigen-presenting cells of myeloid or lymphoid origin, critical for initiating adaptive immune responses. Subsets include conventional (cDC1, cDC2) and plasmacytoid (pDC) dendritic cells. Used in immunotherapy research and vaccine development.
Donor Eligibility Determination
A documented determination under 21 CFR 1271.50 that a donor has been screened and tested in accordance with applicable requirements and is eligible as a source of cells or tissues for use in humans. Required for all OrganaBio GMP-tier products.
E
Engraftment
The process by which transplanted cells establish themselves and begin functioning in the recipient’s body. Successful engraftment is a primary endpoint in stem cell transplantation.
F
Flow Cytometry
A laboratory technique that measures physical and chemical characteristics of cells as they flow through a laser. Used for immunophenotyping, cell counting, and quality control of cell therapy products. OrganaBio offers up to 25-color flow cytometry analysis.
FDA Regulation 21 CFR 1271
The US regulation governing human cells, tissues, and cellular and tissue-based products (HCT/Ps). Covers donor eligibility, current good tissue practice (CGTP), establishment registration, and adverse-event reporting. OrganaBio’s quality system is built to 21 CFR 1271 across both RUO and GMP product tiers.
G
GMP-Grade
Materials manufactured under cGMP conditions suitable for use in clinical trials and commercial therapies. GMP-grade starting materials require documented processes, qualified facilities, and regulatory compliance.
H
HLA (Human Leukocyte Antigen)
Proteins on cell surfaces that play a critical role in immune recognition. HLA typing is essential for donor-recipient matching in transplantation and for selecting appropriate donors for allogeneic cell therapy. OrganaBio provides high-resolution HLA typing using next-generation sequencing at 6 loci (A, B, C, DR, DQ, DP).
I
Immunophenotyping
The characterization of cells using antibodies that recognize specific surface markers. Used to identify cell types, assess purity, and verify product quality in cell therapy manufacturing.
IRB (Institutional Review Board)
An ethics committee that reviews and approves research involving human subjects. All donor collections at OrganaBio are conducted under IRB-approved protocols with informed consent.
iPSC (Induced Pluripotent Stem Cell)
A pluripotent stem cell generated by reprogramming somatic cells through defined transcription factors (originally Oct4, Sox2, Klf4, c-Myc). Used as a scalable source for differentiated cell types in allogeneic cell therapy programs.
K
KIR (Killer-cell Immunoglobulin-like Receptor)
A family of receptors expressed on NK cells that regulate their activation through interaction with HLA class I ligands. KIR-ligand mismatching is relevant to allogeneic NK cell therapy and CAR-NK program design.
L
Leukopak
A concentrated collection of white blood cells obtained via leukapheresis. Leukopaks contain T cells, B cells, NK cells, and monocytes and serve as the primary starting material for many cell therapies. OrganaBio’s LeukoPAC products are available fresh or cryopreserved.
M
MSC (Mesenchymal Stem/Stromal Cell)
Multipotent cells that can differentiate into bone, cartilage, and fat cells. MSCs also secrete anti-inflammatory and immunomodulatory factors. OrganaBio’s MesenPAC products provide MSCs from umbilical cord tissue and placental tissue.
Macrophages
Tissue-resident or monocyte-derived phagocytic cells with roles in innate immunity, tissue remodeling, and immune regulation. In vitro, human macrophages are typically differentiated from monocytes using M-CSF or GM-CSF over 5-7 days. OrganaBio supplies primary human macrophages pre-differentiated to defined polarization states (M0, M1, M2).
Monocytes
Circulating myeloid cells identified by CD14 expression, subdivided into classical (CD14++CD16-), intermediate (CD14++CD16+), and non-classical (CD14+CD16++) populations. Precursors to tissue macrophages and dendritic cells. OrganaBio supplies CD14+ monocytes isolated from peripheral blood leukopaks.
N
NK Cell (Natural Killer Cell)
A type of lymphocyte that plays a role in innate immunity by killing virus-infected and cancerous cells. NK cells are increasingly used in cancer immunotherapy, particularly CAR-NK approaches. Cord blood NK cells have advantages including naive phenotype and amenability to genetic modification.
P
PBMC (Peripheral Blood Mononuclear Cell)
A collective term for blood cells with a round nucleus, including lymphocytes (T cells, B cells, NK cells) and monocytes. PBMCs are isolated from whole blood or leukopaks and used extensively in immunology research and clinical monitoring.
Process Development
The systematic optimization of manufacturing processes to achieve robustness, reproducibility, and scalability. OrganaBio offers process development services using equipment including CliniMACS Prodigy, AutoMACS, and Sepax systems.
Placental Tissue
Perinatal tissue obtained at full-term birth, used as a source of mesenchymal stromal cells and extracellular matrix products for research and clinical applications. OrganaBio’s MesenPAC-MSC-PL is derived from ethically consented placental tissue.
Post-Thaw Viability
The percentage of viable cells remaining after a cryopreserved product is thawed using a defined protocol. A standard release criterion on Certificates of Analysis for frozen cell products and a primary determinant of downstream assay quality.
Potency Assay
A quantitative measure of the biological activity of a cell therapy product, required for lot release. For cell therapies, potency assays often measure cytotoxicity, cytokine release, or surface marker function depending on the mechanism of action.
R
RUO (Research Use Only)
Products intended for laboratory research purposes only, not for use in diagnostic procedures or therapeutic applications. RUO products have fewer regulatory requirements than GMP-grade materials but must still meet quality standards.
RUO-to-GMP Transition
The progression from research-grade to clinical-grade materials during the development of a cell therapy. OrganaBio enables seamless RUO-to-GMP transition by using the same donors, SOPs, and team from early research through clinical manufacturing.
S
Starting Material
The biological raw material from which a cell therapy product is manufactured. Common starting materials include leukopaks, cord blood units, and tissue-derived cells. The quality of starting material directly impacts the quality and consistency of the final product.
T
T Cell
A type of lymphocyte central to adaptive immunity. T cells are the basis for CAR-T therapy and play essential roles in immune responses. Different T cell subsets (CD4+ helper, CD8+ cytotoxic) serve different functions.
Tissue Collection
The procurement of biological tissues (such as umbilical cord, placenta, and cord blood) from consenting donors. OrganaBio’s subsidiary GaiaGift manages tissue collection through partnerships with hospitals and OB/GYN practices.
TCR Engineering
A cell therapy modality in which T cells are engineered to express a defined T cell receptor that recognizes a tumor-associated peptide presented by HLA. Requires HLA-matched patients and high-resolution HLA typing of starting material across HLA-A, -B, -C, -DRB1, -DQB1, and -DPB1.
Tregs (Regulatory T Cells)
A subset of CD4+ T cells characterized by high CD25 and FOXP3 expression, responsible for immune tolerance and suppression of autoreactive responses. Used in autoimmune disease therapy development and graft-versus-host disease research.
U
Umbilical Cord Tissue
The structural tissue of the umbilical cord, primarily Wharton’s jelly, used as a source of mesenchymal stromal cells. Collected at birth under IRB-approved consent and processed into tissue-derived MSC products. OrganaBio’s MesenPAC-MSC-UC is derived from umbilical cord tissue collected through the GaiaGift subsidiary.
V
Vertical Integration
A business model where a company owns and operates multiple stages of its supply chain. OrganaBio is vertically integrated from donor recruitment (HemaCenter, GaiaGift) through collection, processing, manufacturing, analytical testing, and logistics, maintaining a single chain of custody and quality system throughout.
Additional terms
AAV (Adeno-Associated Virus)
A small, non-pathogenic virus used as a vector for in vivo gene therapy. Different AAV serotypes (AAV2, AAV5, AAV8, AAV9) preferentially target different tissues. Most FDA-approved in vivo gene therapies to date use AAV vectors.
Aseptic Processing
Manufacturing conducted under conditions designed to prevent microbial contamination of a product that cannot be terminally sterilized. The dominant approach for cell therapy products, which are too fragile for heat or filter sterilization.
ATMP (Advanced Therapy Medicinal Product)
The European Medicines Agency regulatory category covering gene therapy, somatic cell therapy, tissue-engineered, and combined ATMPs. Roughly corresponds to the FDA cell and gene therapy product categories.
B Cells
A class of lymphocyte responsible for producing antibodies. Identified by CD19 and CD20 surface markers. Used in research on humoral immunity, vaccine response, and B-cell malignancies.
Base Editing
A gene editing approach that converts one DNA base into another without making double-stranded breaks. Considered safer than CRISPR-Cas9 for some applications because it avoids the risks associated with DNA cleavage.
Bioreactor
A controlled vessel in which cells are expanded under defined conditions of temperature, pH, oxygen, and nutrient feed. Cell therapy bioreactor types include rocking bag systems, stirred-tank, and gas-permeable static culture.
BLA (Biologics License Application)
A submission to the FDA requesting approval to market a biological product. For cell and gene therapies, the BLA includes manufacturing, preclinical, and clinical data. Approval transitions a product from investigational (IND) to commercial.
Cell Selection
The process of isolating a specific cell population from a heterogeneous mixture. Common methods include magnetic-bead-based selection (positive or negative) and fluorescence-activated cell sorting (FACS).
Cell Therapy
The therapeutic administration of living cells to treat disease. Includes both autologous (patient-derived) and allogeneic (donor-derived) approaches, using unmodified, expanded, or genetically engineered cells.
CliniMACS
Miltenyi Biotec clinical-grade magnetic cell separation system, widely used in cell therapy manufacturing for selecting populations such as CD34+ HSCs or CD3+ T cells.
Closed-System Manufacturing
A manufacturing approach in which cells are processed in a sealed flow path that eliminates exposure to the external environment. Required for many cGMP cell therapy products to maintain sterility.
CMC (Chemistry, Manufacturing, and Controls)
The section of an IND or BLA describing how the biological product is made, tested, and controlled. For cell therapies, CMC documentation includes starting material specifications, manufacturing process, in-process testing, and final product release criteria.
CMV (Cytomegalovirus)
A herpesvirus that can cause significant disease in immunocompromised patients. Donor screening for CMV antibodies is required for cell and tissue donors under 21 CFR 1271. Some applications require CMV-negative starting material.
CRISPR-Cas9
A gene editing system using a guide RNA and Cas9 nuclease to make targeted cuts in DNA. The basis for Casgevy, the first FDA-approved CRISPR-edited cell therapy, approved December 2023 for sickle cell disease and beta-thalassemia.
Cryomedium
The solution in which cells are frozen, typically containing DMSO (5 to 10 percent) as a cryoprotectant plus a protein source (serum, albumin, or fully defined formulation). Cryomedium choice impacts post-thaw viability and downstream functionality.
Cytokine Release Syndrome (CRS)
A systemic inflammatory response triggered by some cell therapies (notably CAR-T) as activated immune cells release cytokines. Severity ranges from mild fever to life-threatening multi-organ dysfunction. Managed with tocilizumab, corticosteroids, and supportive care.
DMF (Drug Master File)
A confidential FDA submission filed by a supplier of a component used in a drug product. Allows the supplier to share proprietary manufacturing details with the FDA without disclosing them to the drug sponsor. Starting material suppliers commonly file Type II DMFs.
EBV (Epstein-Barr Virus)
A herpesvirus that establishes lifelong latency in B cells and can transform infected cells. Donor screening required under 21 CFR 1271.
Endotoxin Testing
Quantification of bacterial endotoxin (lipopolysaccharide) in a cell product. Required by USP 85. Limits for cell therapy products are typically set per the intended dose and route of administration.
Gamma-Delta T Cells
A minor subset of T cells (1 to 10 percent of circulating T cells) that recognize antigens independently of MHC presentation. Of growing interest as an allogeneic platform for cell therapy because of reduced GvHD risk.
GCP (Good Clinical Practice)
International standards for the design, conduct, and reporting of clinical trials. Codified in ICH E6 and required for any clinical trial intended to support a regulatory submission.
Gene Therapy
The introduction, removal, or modification of genetic material to treat disease. Includes both ex vivo approaches (modifying cells outside the body, then reinfusing) and in vivo approaches (delivering genetic material directly into the patient).
GLP (Good Laboratory Practice)
FDA regulations (21 CFR Part 58) covering non-clinical laboratory studies. Required for the preclinical safety data used to support an IND submission.
GTP (Good Tissue Practice)
FDA regulations (21 CFR Part 1271 Subpart D) for the recovery, processing, storage, and distribution of human cells, tissues, and cellular and tissue-based products.
GvHD (Graft-versus-Host Disease)
An immune reaction in which donor immune cells attack the recipient tissues. The primary safety concern for allogeneic cell therapies. Manufacturing strategies to reduce GvHD include T cell depletion and TCR gene editing.
HBV/HCV Hepatitis Screening
Required donor screening under 21 CFR 1271 for hepatitis B and C infection. Both serology and nucleic acid testing (NAT) are required.
HCT/P (Human Cells, Tissues, and Cellular and Tissue-Based Products)
The FDA regulatory category for products containing or derived from human cells or tissues. Governs starting materials used in cell and gene therapy. Detailed in 21 CFR Part 1271.
HIV (Human Immunodeficiency Virus)
The virus that causes AIDS. Donor screening (both NAT and serology) is mandatory under 21 CFR 1271 for all cell and tissue donors.
ICANS (Immune Effector Cell-Associated Neurotoxicity Syndrome)
A neurologic toxicity associated with CAR-T cell therapy, ranging from headache and confusion to seizure and cerebral edema. Managed with corticosteroids and supportive care.
ICH (International Council for Harmonisation)
The body that develops unified technical standards for pharmaceutical regulation across the US, EU, and Japan. Key ICH guidelines for cell therapy include Q5A (viral safety) and Q5E (comparability).
IND (Investigational New Drug)
The FDA submission required before a new biological product can be tested in humans. The IND includes preclinical data, manufacturing information, and the proposed clinical protocol. Sponsors cannot begin clinical trials until the IND is in effect.
IND-Enabling Study
Preclinical work designed to support the safety package required for an IND submission. For cell therapies this typically includes biodistribution, toxicology, and tumorigenicity studies in animal models.
Lot Release Testing
The full panel of tests run on each manufactured lot before release. For cell therapy starting material, this typically includes sterility, mycoplasma, endotoxin, identity, purity, and viability.
LRS Chamber (Leukoreduction System Chamber)
A byproduct of platelet apheresis containing concentrated leukocytes that would otherwise be discarded. A cost-effective source of PBMCs and other leukocytes for research and development work.
MCB (Master Cell Bank)
The original, qualified cell stock from which all working cell banks are derived. Stored as a single homogeneous lot under tightly controlled conditions. Characterized for identity, purity, sterility, and absence of adventitious agents.
Memory T Cells
Long-lived T cells that respond rapidly to re-exposure to a previously encountered antigen. Subtypes include central memory (Tcm) and effector memory (Tem), differentiated by CD45RA, CD45RO, CCR7, and CD62L expression.
Mobilized PBMC
PBMCs collected after a donor has been treated with G-CSF or plerixafor, which mobilizes hematopoietic stem and progenitor cells from bone marrow into the peripheral blood. The standard source for autologous HSC transplant.
Mycoplasma Testing
Release test for the presence of Mycoplasma, a cell-wall-deficient bacterial contaminant common in cell culture. Required by USP 63 and 21 CFR 610.30. Rapid PCR-based methods are increasingly used to shorten release timelines.
Naive T Cells
T cells that have not yet encountered their cognate antigen. Marked by CD45RA+ and CCR7+ expression. Often preferred for CAR-T manufacturing because of greater proliferative capacity and persistence post-infusion.
Off-the-Shelf Therapy
An allogeneic cell therapy product that can be administered to any compatible patient without individualized per-patient manufacturing. Contrast with autologous products, which require per-patient manufacturing.
Persistence
The duration that infused cell therapy products remain functional in the patient. Critical for sustained therapeutic effect, particularly in CAR-T and TCR therapies.
Pre-IND Meeting
An optional FDA meeting where a sponsor presents their development plan and receives agency feedback before submitting an IND. Common for cell and gene therapy programs because the regulatory path is more individualized than for small molecules.
Prime Editing
A gene editing method that uses a Cas9 nickase fused to a reverse transcriptase, enabling all 12 possible base-to-base conversions plus small insertions and deletions without double-strand breaks.
Regenerative Medicine
A field that aims to restore the function of damaged tissues and organs, typically using cell therapy, biomaterials, or tissue engineering. Encompasses stem cell therapy, gene therapy, and engineered tissue products.
Single-Use Technology (SUT)
Disposable, sterile manufacturing components (bags, tubing, filters, bioreactors) used once and discarded. Reduces cleaning validation burden and cross-contamination risk; standard in modern cell therapy facilities.
Sterility Testing
Required release test confirming the absence of viable microorganisms in a cell product. Compendial methods include USP 71 and the rapid sterility tests (USP 1071) increasingly accepted by the FDA for short-shelf-life cell therapies.
T Cells
A class of lymphocyte central to cell-mediated immunity. Subtypes include CD4+ helper T cells, CD8+ cytotoxic T cells, and regulatory T cells. The substrate for most CAR-T and TCR therapy programs.
TALEN (Transcription Activator-Like Effector Nuclease)
A gene editing system that pairs a programmable DNA-binding domain with a FokI nuclease. Used in some cell therapy products as an alternative to CRISPR.
TIL (Tumor-Infiltrating Lymphocytes)
Lymphocytes that have migrated into a tumor. TIL therapy involves isolating these cells, expanding them ex vivo, and infusing them back into the patient. Lifileucel (Amtagvi) was the first FDA-approved TIL therapy, approved February 2024.
Vapor-Phase Storage
Long-term storage of cryopreserved cells in the vapor phase above liquid nitrogen rather than in the liquid itself. Reduces cross-contamination risk and is preferred for clinical-grade samples.
WCB (Working Cell Bank)
The cell bank derived from the MCB and used for routine manufacturing. Typically aliquoted into many vials, each used to start a manufacturing run.
WNV (West Nile Virus)
A mosquito-borne flavivirus. Donor screening required under 21 CFR 1271 for human cells and tissues collected during transmission seasons.
